Nefazodone dosage form
Patent 6143325 Issued on November 7, 2000. Estimated Expiration Date: 
April 26, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 26, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesControlled release formulation Buoyant controlled release powder formulation Method for administration of buspirone Colonic drug delivery system Patent #: 5536507 InventorsAssigneeApplicationNo. 299959 filed on 04/26/1999US Classes:424/468, Sustained or differential release type424/464, Tablets, lozenges, or pills424/474, Coated pills or tablets424/480, Cellulose or derivative514/254.05, Plural nitrogens in the additional five-membered hetero ring514/255.03, Carbocyclic ring bonded directly to the piperazine ring514/384Chalcogen bonded directly to the triazole ringExaminersPrimary: Page, Thurman K.Assistant: Pulliam, Amy E Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/22A61K 009/28 A61K 031/495 A61K 031/419.6 AbstractExtended-release nefazodone compositions containing nefazodone hydrochloride, ionic and non-ionic gelling polymers, an insoluble hydrophilic agent, and optional pharmaceutically acceptable excipients demonstrate pH-modulated release of nefazodone. These compositions are formulated into unit dosage forms for improved oral administration. The improvements comprise an extended drug release profile providing comparative levels of nefazodone with respect to immediate release dosage forms and, additionally, demonstrating the lack of a food effect.Other References
| |
